Completed Studies - Diabetes
ACHIEVE-3
J2A-MC-GZGU A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Oral LY3502970 Once Daily Compared to Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3)
MK 0431-845
MK0431-845
Phase III, multicenter, randomized, double-blind, placebo-controlled clinical study to study the efficacy and safety of continued administration of sitagliptin compared to withdrawal of sitagliptin during initiation and titration of insulin glargine (LANTUS®) in participants with type 2 diabetes mellitus
MK 8835-001
MK 8835-001
“Phase III, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in subjects with type 2 diabetes mellitus with stage 3 chronic kidney disease, “whose glycemic control is inadequate with basic antihyperglycemic treatment”
DIA 4003
Protocol 28431754DIA4003
“Randomized, multicenter, double-blind, parallel, placebo-controlled study of the effects of canagliflozin on renal endpoints in adult subjects with type 2 diabetes mellitus.”
HARMONY
LPG 116174
“Long-term, randomized, double-blind, placebo-controlled study to determine the effect of albiglutide added to standard blood glucose-lowering therapies on major cardiovascular events in patients with Type 2 diabetes mellitus.”
VERTIS
MK-8835-004-01/ B1521021
“Randomized, double-blind, placebo-controlled, parallel-group study to evaluate cardiovascular outcomes after treatment with ertugliflozin (MK-8835/PF-04971729) in subjects with type 2 diabetes mellitus and established vascular disease,” the cv study "Vertis."
ABBVIE
Estudio aleatorizado, multipaís, multicéntrico, a doble ciego, paralelo y controlado con placebo sobre los efectos de atrasentan en resultados renales de sujetos con diabetes tipo 2 y nefropatía. SONAR: estudio de nefropatía diabética con atrasentan
SCORED
EFC14875 – SCORED - Multicenter, randomized, double-blind, placebo-controlled, parallel-group study to demonstrate the effects of sotagliflozin on cardiovascular and renal events in patients with type 2 diabetes, cardiovascular risk factors and moderate renal failure
